Impact Therapeutics-B (07630.HK): Senaparib receives positive CHMP opinion, expected to be used for first-line maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer

Zhitong Finance APP News, IMPACT Therapeutics-B (07630.HK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of the marketing authorization (MA) for Sepalna (senaparib), which is intended for the maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.